



August 8, 2014

ViperGen presents the first discovery of a single digit nanomolar small molecule blocker of a protein-protein interaction target.

Copenhagen, Denmark, August 8, 2014 - - ViperGen ApS today announced that the first discovery of single digit nanomolar small molecule protein-protein interaction blockers will be presented at the 2nd Protein-Protein Interaction Conference to be held on October 23-24, 2014 in Boston, MA.

“Our data demonstrate that ViperGen’s two 2nd generation technologies, YoctoReactor® and Binder Trap Enrichment®, for small molecule drug discovery, rapidly and seamlessly identify novel and potent hit series for even “hard-to-drug” targets, including protein-protein interactions targets” said Dr. Nils Hansen, CEO of ViperGen ApS. “So far, discovery of small molecule PPI blockers as such has been limited due to technological hurdles; hits previously identified typically had modest potencies in the high nanomolar to micromolar range. The PPI target, interleukin 6 receptor (IL-6R) is a clinically validated target implicated in cancer, and in multiple inflammatory and autoimmune diseases. ViperGen has discovered single digit nanomolar potency hits (MW ~500 Da) for this valuable target, comprising two chemical series. Clear structure activity relationships are instantly revealed permitting instant determination of the core motif (350 Da) while maintaining good potency of 16 nM. Our findings represent about a 1000 fold increase in potency over PPI blockers previously discovered. We believe these results are a major leap forward for developing orally bioavailable therapeutics for this important yet untapped target class”

Presentation:

‘Discovery of the first single digit nanomolar small molecule PPI blockers’, Nils Hansen, Ph.D. – Chief Executive Officer, ViperGen ApS, Thursday, October 23, 2014, 2:20 pm, Session: Protein-Protein Interactions - Design & Evolution

About ViperGen ApS

ViperGen is dedicated to small molecule drug discovery using DNA-encoded small-molecule libraries.

ViperGen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.

ViperGen’s two 2nd generation technology platforms - The YoctoReactor® for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment® for screening of such libraries - are designed to deliver high fidelity drug discovery.

For further details about ViperGen and the YoctoReactor®/ Binder Trap Enrichment® drug discovery technology platforms please contact:

ViperGen ApS

Nils Hansen, CEO

Phone: +45 2523 6680

nha@viperGen.com